| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Published online before print February 14, 2008
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From INSERM U858,*Toulouse Cedex, France; INSERM U689,Centre de Recherche Cardiovasculaire Inserm Lariboisière, Paris, France; INSERM U828,Pessac, France; and Unité de Pharmacothérapie,Université Catholique de Louvain, Brussels, Belgium
We have previously shown that estrogen exerts a vasoprotective effect by accelerating reendothelialization after perivascular artery injury through activation of the estrogen receptor 
. Because 17β-estradiol (E2) is known to increase the bioavailability of nitric oxide, in this study, we used the same perivascular model to characterize the role of the endothelial nitric oxide synthase (eNOS) pathway in reendothelialization. Surprisingly, we found that the stimulatory effect of E2 on reendothelialization was not altered following pharmacological inhibition of nitric-oxide synthase enzymatic activity by N-nitro-L-arginine methyl ester, whereas it was abolished in eNOS-deficient (eNOS–/–) mice. This discrepancy between eNOS gene inactivation and the pharmacological inhibition of eNOS was confirmed in a classical model of endovascular injury. When assessing the involvement of eNOS in short-term membrane-associated signaling events induced by E2, we found that E2 stimulated phosphorylation of extracellular signal-regulated kinase 1/2 in isolated perfused carotid arteries from wild-type mice in the absence or presence of N-nitro-L-arginine methyl ester, whereas this stimulation was abolished in carotid arteries from eNOS–/– mice. Similar results were obtained in primary cultures of mouse aortic endothelial cells. These data reveal an original and unexpected role of eNOS, in which its presence but not its enzymatic activity appears to be a determinant for estrogen signaling in the endothelium. The consequences of this novel function of eNOS with respect to vascular diseases should be explored.
This article has been cited by other articles:
 |
|
 |
|
  T. Imanishi, H. Tsujioka, and T. Akasaka Endothelial progenitor cell senescence is there a role for estrogen? Therapeutic Advances in Cardiovascular Disease, February 1, 2010; 4(1): 55 - 69. [Abstract] [PDF]
|
|
|
|
 |
|
 J.-L. Balligand, O. Feron, and C. Dessy eNOS Activation by Physical Forces: From Short-Term Regulation of Contraction to Chronic Remodeling of Cardiovascular Tissues Physiol Rev, April 1, 2009; 89(2): 481 - 534. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Billon-Gales, C. Fontaine, C. Filipe, V. Douin-Echinard, M.-J. Fouque, G. Flouriot, P. Gourdy, F. Lenfant, H. Laurell, A. Krust, et al. The transactivating function 1 of estrogen receptor {alpha} is dispensable for the vasculoprotective actions of 17{beta}-estradiol PNAS, February 10, 2009; 106(6): 2053 - 2058. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. G.M. Molin, N. M.S van den Akker, and M. J. Post Affirmative Action of Osteopontin on Endothelial Progenitors Arterioscler Thromb Vasc Biol, December 1, 2008; 28(12): 2099 - 2100. [Full Text] [PDF]
|
|
|
|
|
|
L. Lam Shang Leen, C. Filipe, A. Billon, B. Garmy-Susini, S. Jalvy, F. Robbesyn, D. Daret, C. Allieres, S. R. Rittling, N. Werner, et al. Estrogen-Stimulated Endothelial Repair Requires Osteopontin Arterioscler Thromb Vasc Biol, December 1, 2008; 28(12): 2131 - 2136. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Filipe, L. Lam Shang Leen, L. Brouchet, A. Billon, V. Benouaich, V. Fontaine, P. Gourdy, F. Lenfant, J.-F. Arnal, A.-P. Gadeau, et al. Estradiol accelerates endothelial healing through the retrograde commitment of uninjured endothelium Am J Physiol Heart Circ Physiol, June 1, 2008; 294(6): H2822 - H2830. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
